Want to see FR:MEDCL full AI Analyst Report?
MEDCL Stock Chart & Stats
€26.00
€0.00(0.00%)
At close: 4:00 PM EDT
€26.00
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€16.64 - €39.68
Previous CloseN/A
Volume58.40K
Average Volume (3M)179.66K
Market Cap
€866.11M
Enterprise Value€731.65
Total Cash (Recent Filing)€84.82M
Total Debt (Recent Filing)€57.41M
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Dec 08, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.91
Shares Outstanding35,912,260
10 Day Avg. Volume204,359
30 Day Avg. Volume179,664
Financial Highlights & Ratios
PEG Ratio-0.68
Price to Book (P/B)264.15
Price to Sales (P/S)41.46
P/FCF Ratio-30.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€38.00Price Target Upside46.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.04
Revenue Forecast (FY)€47.41M
Bulls Say, Bears Say
Bulls Say
Growing Recurring Royalty BaseThe rising royalty mix and strong UZEDY sales create a more recurring revenue base, reducing reliance on one-off milestones. Continued partner-led commercial growth could improve revenue visibility and support operating leverage over the medium term.
Olanzapine LAI Regulatory ProgressAcceptance of the NDA materially advances a potential second royalty-generating product. The subcutaneous formulation has more than 4,000 clinical injections without PDSS events, supporting differentiation if approval and launch milestones are achieved.
Broad Partnered Development PipelineA broad pipeline and partner-funded development model diversify future commercialization opportunities while limiting some internal funding requirements. Progress with AbbVie and other programs can extend the BEPO platform's long-term royalty potential.
Bears Say
Persistent Losses And Negative MarginsThe company remains structurally loss-making despite revenue scaling, and losses widened in the latest year. Limited operating leverage means profitability still depends on successful product launches, royalty growth and disciplined investment over time.
Cash Burn And Thin Equity CushionSignificant cash consumption combined with a thin equity base increases funding sensitivity. Even with reported net cash, continued R&D and business development spending may require monetization progress or external capital if royalty growth is delayed.
Dependence On Partners And Regulatory TimingMedinCell relies on partners for commercialization, development decisions and regulatory execution. Delayed approvals, conservative partner guidance or changes to program pathways could postpone royalties and make the pipeline's economic contribution less predictable.
MedinCell SA News
MEDCL FAQ
What was MedinCell SA’s price range in the past 12 months?
MedinCell SA lowest stock price was €16.64 and its highest was €39.68 in the past 12 months.
What is MedinCell SA’s market cap?
MedinCell SA’s market cap is €866.11M.
When is MedinCell SA’s upcoming earnings report date?
MedinCell SA’s upcoming earnings report date is Dec 08, 2026 which is in 107 days.
How were MedinCell SA’s earnings last quarter?
MedinCell SA released its earnings results on Jun 16, 2026. The company reported -€0.45 earnings per share for the quarter, missing the consensus estimate of -€0.14 by -€0.31.
Is MedinCell SA overvalued?
According to Wall Street analysts MedinCell SA’s price is currently Undervalued.
Does MedinCell SA pay dividends?
MedinCell SA does not currently pay dividends.
What is MedinCell SA’s EPS estimate?
MedinCell SA’s EPS estimate is -0.22.
How many shares outstanding does MedinCell SA have?
MedinCell SA has 35,912,260 shares outstanding.
What happened to MedinCell SA’s price movement after its last earnings report?
MedinCell SA reported an EPS of -€0.45 in its last earnings report, missing expectations of -€0.14. Following the earnings report the stock price went up 0.719%.
Which hedge fund is a major shareholder of MedinCell SA?
Currently, no hedge funds are holding shares in FR:MEDCL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MedinCell SA
MedinCell S.A. specializes in pioneering diverse therapeutic treatments. At the core of its development lies BEPO, a cutting-edge technology that enables the creation of long-acting injectable pharmaceutical products. This system leverages a unique combination of proprietary copolymers and a biocompatible solvent to effectively dissolve or suspend active drug compounds. The company's advanced pipeline includes several key products: mdc-IRM, a subcutaneous injection currently in Phase III clinical trials for the treatment of schizophrenia; mdc-CWM, an intra-articular injection designed to address pain and inflammation; and mdc-TJK, another subcutaneous injection targeting schizophrenia, presently in preclinical development. MedinCell is also actively engaged in formulation research for additional product candidates. These encompass subcutaneous injections such as mdc-WWM for contraception, mdc-ANG for central nervous system-related conditions, mdc-ELK for depression, and mdc-GRT for organ transplant applications. Furthermore, the firm is investigating perineural injections like mdc-CMV for anesthesia and pain management, and mdc-NVA, also intended for pain relief. MedinCell S.A. maintains its headquarters in Jacou, France.
MEDCL Stock 12 Month Forecast
Average Price Target
€38.00
▲(46.15% Upside)